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Influence of p53 Isoform Expression 
on Survival in High-Grade Serous 
Ovarian Cancers
Katharina Bischof1,2, Stian Knappskog3,4, Sigrun M. Hjelle1,7, Ingunn Stefansson5,6, 
Kathrine Woie2, Helga B. Salvesen1,2, Bjorn T. Gjertsen  1,7 & Line Bjorge1,2
High-grade serous ovarian carcinoma (HGSOC) is characterised by alterations in the p53 pathway. The 
expression levels of p53 isoforms have been shown to be associated with patient survival in several 
cancers. This study examined the predictive and prognostic effects of the expression levels of TP53 pre-
mRNA splicing isoforms and TP53 mutations in tumour tissues in 40 chemotherapy responders and 29 
non-responders with HGSOC. The mRNA expression levels from total p53, and total Δ133p53, p53β, 
p53γ isoforms were determined by RT-qPCR, and TP53 mutation status by targeted massive parallel 
sequencing. The results from these analyses were correlated with the clinical outcome parameters. 
No differential expression of p53 isoforms could be detected between the chemosensitive and 
chemoresistant subgroups. In a multivariate Cox regression model, high levels of total Δ133p53 were 
found to be an independent prognosticator for improved overall survival (HR = 0.422, p = 0.018, 95% CI: 
0.207–0.861) and reached borderline significance for progression-free survival (HR = 0.569, p = 0.061, 
95% CI: 0.315–1.027). TP53 mutations resulting in loss of function or located at known hotspots 
were predictive of tumour characteristics and disease progression. These findings suggest that total 
Δ133p53 mRNA can be a biomarker for survival in HGSOC.
Mutations in the TP53 gene are early and almost ubiquitous events in the genesis of high-grade serous ovarian 
carcinoma (HGSOC)1–4. Although various classes of mutations occur throughout the coding region of the TP53 
gene in human cancers, there is a clear enrichment of missense or nonsense single base substitutions affecting the 
DNA-binding domain of the protein5. Since large-scale sequencing data for TP53 mutations became available, 
the predictive and prognostic roles of defined subcategories of TP53 mutations have been extensively investi-
gated. Alterations that result in a loss of function (LOF) or oncogenic mutations conferring to tumour-promoting 
abilities have been shown to be associated with chemoresistance and worse survival in ovarian cancers6–9. Small 
molecule therapies targeting mutated p53 proteins in cancer cells are under development for the treatment of 
ovarian cancer and may lead to TP53 mutational guided therapy10,11.
In humans, the TP53 gene encodes RNA that is edited by pre-mRNA splicing, yielding at least 12 protein 
isoforms expressed to various degrees in different tissues and under various physiological conditions12 (Fig. 1). 
Emerging evidence has linked the deregulated expression of these isoforms to cancer13–18. The amino-terminally 
truncated Δ133p53 isoform is the product of alternative promoter usage and has been shown to exert 
dominant-negative functions toward canonical p53 in colon cancer cell line models18. In addition, Δ133p53 has 
been shown to inhibit replicative senescence and to promote cellular proliferation13. The biological role of the 
carboxy-terminally truncated p53β and p53γ isoforms, both products of alternative splicing of intron 918–20, is still 
being debated. However, these isoforms have been shown to enhance p53´s tumour-suppressive transcriptional 
activity of Bax and p2121,22.
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Figure 1. (A) Overview of FIGO disease stages represented by the series for this study and illustration of 
sample collection and extraction of DNA and RNA. (B) Structure of the human TP53 gene comprising 11 
exons. P1 = proximal promoter encoding full-length p53, P2 = internal promoter resulting in Δ133p53 
product. Alternative splicing sites (^). Primer location is indicated by coloured arrows and is indexed on the 
lower left. (C) Provides a more detailed schematic illustration of the distinct functional and structural domains 
of the 393 amino acid long p53 protein. TA1 and TA2 form the transactivation domain, followed by the proline 
rich domain (PD) and the DNA binding domain, where the three most frequently found point mutations in 
high-grade serous gynaecological cancers are indicated. The tetramerization domain (TET) and basic region 
(BR) form the C-terminus. (D) Illustrates the exon composition of canonical p53 and relevant p53 isoforms. 
Abbreviations: Transactivation domain (TA), DNA binding domain (DBD), C-terminal oligomerization 
domain (OD). The N-terminally truncated isoform Δ133p53 is a product of the regulation of an internal 
promoter in intron 4 (P2). The C-terminally altered p53β and p53γ isoforms have alternative sequences after 
amino acid 332. Molecular weight indicated in kilodalton (kd) on the right side.
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Previous studies, including those by the authors, have reported that in gynaecological malignancies, such as 
epithelial ovarian cancers and uterine serous cancers, the altered expression of the p53 isoforms was associated 
with tumour traits, such as grade of differentiation, sensitivity to chemotherapy and survival23–26.
Chemotherapy resistance remains a major obstacle in the successful treatment of patients with HGSOC. 
Data from high-resolution copy-number profiles on tumour samples collected throughout therapy indicate that 
HGSOC already exhibits substantial clonal diversity at primary diagnosis27; therefore, the high rates of acquired 
chemoresistance may be a result of subset selection with primary innate chemoresistance28.
In the current study, we aimed to investigate the predictive and prognostic impact of the p53 isoforms in a 
cohort of HGSOC patients selected based on their response or non-response to chemotherapy. The potential pre-
dictive and prognostic roles were explored based on the mRNA expression levels of the individual TP53 isoforms 
in HGSOC tumour tissue (Fig. 1C). High mRNA levels of the amino-terminally altered total Δ133p53 isoform 
were associated with favourable survival. These findings suggest the total Δ133p53 isoform to be a possible bio-
marker for disease progression in HGSOC, worthy of further validation.
Results
Prognostic value of clinical characteristics. The sample in the present study comprised 69 patients with 
HGSOC. These 69 cases were selected from a cohort of 493 epithelial ovarian cancers (EOCs) (see Methods sec-
tion) based on their poor (n = 29) responses or good (n = 40) responses to adjuvant treatment with carboplatin 
and taxane, thus representing chemoresistant and chemosensitive subsets, respectively. A poor response to adju-
vant therapy was defined as disease progression after ≤6 months after completed primary platinum/taxane based 
chemotherapy, and a good response was ≥17 months of progression-free survival (PFS). The mean age at the time 
of diagnosis was 59 (range 31–75) for poor responders and 61 (range 44–77) for good responders. It was noted 
that 72% (21 of 29) of the poor responders presented with International Federation of Gynecology and Obstetrics 
(FIGO) stage IIIC disease at the time of primary treatment, and 90% (36 of 40) of good responders were diag-
nosed at stage IIIC. In both cohorts, a majority of the tumours exhibited high-grade differentiation (see Table 1.)
Univariate and multivariate Cox regression analyses (see Table 2) were performed to determine the prognos-
tic relevance of the clinicopathological prognosticators in the combined sample set (n = 69), and disease stage 
was found to be a predictor of PFS (univariate analysis [p = 0.007]; multivariate analysis [hazard ratio = 2.317, 
p = 0.033, 95% CI: 1.071–5.012]). The results of the univariate analysis showed disease stage to be significantly 
associated with overall survival (OS), (p = 0.002), and the results of the multivariate model showed borderline 
significance (hazard ratio = 2.299, p = 0.051, 95% CI: 0.998–5.297). The presence of residual disease after sur-
gery also had an effect on PFS, as seen in the univariate risk model (p = 0.032), and OS, as seen in the univariate 
analysis (p = 0.017) and the multivariate analysis (hazard ratio = 3.735, p = 0.041, 95% CI: 1.054–13.240). Other 
clinicopathological variables, such as patient age and tumour grade, had no significant effect on the survival 
parameters.
mRNA levels of p53 isoforms in HGSOC. The levels of the total p53 mRNA were quantified, and 
breakpoint-specific qPCR assays were applied to detect the amino-terminal truncated total Δ40p53 and total 
Δ133p53 isoforms, and the carboxy-terminal truncated p53β and p53γ isoforms. Thus, the levels of the p53 tran-
scripts containing each of the breakpoints, but not the combined mRNA species (e.g. Δ133p53β and Δ133p53γ) 
could be quantified. We identified the p53 isoforms total Δ133p53 and the splice isoforms p53β and p53γ in all 
but one of the samples (68 of 69); however, the expression levels of the total Δ40p53 mRNA could not be traced in 
any of the analysed samples. The landscape of the p53 isoforms was dominated by total ∆133p53 isoforms, which 
Clinical parameters Poor response Good response
Mean (range) Mean (range)
Age at diagnosis; in years 59 (31–75) 61 (44–77)
Time to progression; in months 3 (1–6) 42 (17–137)
N (%) N (%)
Tumor grade
   Grade 2 8 (28%) 7 (17%)
   Grade 3 21 (72%) 33 (83%)
FIGO stage
   IIIC 21 (72%) 36 (90%)
   IV 8 (28%) 4 (10%)
Macroscopic surgical resection (data missing for 5 respectively 8 cases)
Complete — 16 (50%)
   Residual disease ≤1 cm 16 (67%) 12 (38%)
   Residual disease >1 cm 8 (33%) 4 (12%)
Table 1. Distribution of clinicopathologic characteristics for 69 patients within subgroups of high grade FIGO 
stages ≥ IIIC enriched for either good response; ≥17 months progression free survival after completed primary 
treatment (surgery followed by adjuvant chemotherapy) or poor response with disease progression within 6 
months after completed primary treatment.
4Scientific RepoRts |          (2019) 9:5244  | https://doi.org/10.1038/s41598-019-41706-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
represented up to 50.6% of the total p53 mRNA; p53β and p53γ accounted for a maximum of 3.3% and 2.5% of 
the total pool of p53 isoforms, respectively (Fig. 2A) The p53γ isoform showed the largest variability between the 
lowest and the highest expressing samples (108-fold). The differences between the highest and the lowest express-
ing samples for the p53β and total ∆133p53 isoforms were 86-fold and 54-fold, respectively.
Correlation between levels of p53 isoforms and total p53. The mRNA levels of the total Δ133p53 
isoforms and the p53β and p53γ isoforms were all highly significantly correlated (p53β vs. p53γ R = 0.896, 
p < 0.001; p53β vs. total Δ133p53 R = 0.494, p < 0.001; p53γ vs. total Δ133p53 γ R = 0.459, p < 0.001; Fig. 2B). 
The expression levels of the individual isoforms were found to be independent of the total p53 levels (p > 0.25 for 
all of the comparisons; Fig. 2C).
Relative expression of p53 isoforms to total p53 associated with TP53 mutation status. The 
levels of total p53 were significantly lower in the TP53 wild-type tumours (n = 5) than in the mutated speci-
mens (n = 26; p = 0.036) (Fig. 3A). While the absolute mRNA levels of the p53 isoforms were not correlated with 
Progression-free survival Multivariate Overall survival Multivariate
Univariate P-value HR (95% CI) P-value Univariate P-value HR (95% CI) P-value
Age at diagnosis; in years 0.557 0.994 (0.958–1.032) 0.77 0.257 0.976 (0.934–1.021) 0.292
Disease stage III vs. IV 0.007 2.317 (1.071–5.012) 0.033 0.002 2.299 (0.998–5.297) 0.051
Tumor grade II vs. III 0.65 0.843 (0.411–1.731) 0.643 0.956 1.135 (0.456–2.826) 0.785
Residual disease 0 vs >0 0.032 1.810 (0.830–3.950) 0.136 0.017 3.735 (1.054–13.240) 0.041
Table 2. Established, clinical prognosticators for survival in univariate and multivariate Cox regression analysis 
in 69 patients with HGSOC. Abbrevations: HR = Hazard ratio. CI = Confidence interval.
Figure 2. mRNA expression of p53 isoforms in tumour samples illustrated as (A). Histogram displaying 
fractions of p53 isoforms to total p53 mRNA in individual specimens. (B) Expression of p53 isoforms between 
each other; p53γ versus p53β, p53β versus Δ133p53, p53γ versus Δ133p53. (C) Expression levels of total p53, 
together with individual p53β, Δ133p53 and p53γ isoforms.
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the TP53 mutation status, the relative expression levels of the p53 isoforms as a fraction of the total p53 levels 
were higher in the wild-type specimens compared to the mutated specimens (total Δ133p53 relative to total p53 
[p = 0.036], p53β relative to total p53 [p = 0.006], p53γ relative to total p53 [p = 0.016]; Fig. 3B–D).
Prognostic effect of p53 isoforms. In further analyses, the levels of each isoform and the relative level, 
as a fraction of the total p53 levels, were used for comparisons with the clinical parameters. In the univariate OS 
analysis, the relative expression of total Δ133p53 was weakly associated with the prognosis (logrank p = 0.173; 
Fig. 4A). This association was further examined in a Cox proportional-hazards survival model. Known clinical 
prognostic factors for ovarian cancer patients (age at diagnosis grouped by median, tumour stage and presence 
of residual tumour) were introduced as binary variables, together with the relative Δ133p53 expression grouped 
by median (Δ133p53ratio high vs. low). The relative expression of total Δ133p53 isoforms to total p53 was found 
to be associated with longer OS (hazard ratio = 0.422, p = 0.018, 95% CI: 0.207–0.861 Table 3). For the other 
isoforms, no prognostic role could be established in the univariate analyses (Fig. S1) or the multivariate analyses.
p53 isoforms as predictive marker for sensitivity to chemotherapy. No significant difference was 
observed in the expression levels of the isoforms between the two predefined groups of chemoresistant and che-
mosensitive patients (Δ133p53 p = 0.135; p53β p = 0.961; p53γ p = 0.496; Mann-Whitney rank test). PFS was 
regarded as a surrogate marker for the efficacy of first-line chemotherapy and chemosensitivity. Higher than 
median levels of Δ133p53 were not associated with significantly altered time to progression, based on the results 
of the univariate survival analysis using the Kaplan-Meier estimator (logrank p = 0.216; see Fig. 4B). In the multi-
variate survival analyses, the expression of Δ133p53 grouped by median (Δ133p53 high vs. low) reached border-
line significance for PFS (hazard ratio = 0.569, p = 0.061, 95% CI: 0.315–1.027 Table 3). For the other isoforms, 
the results of the univariate analyses (Fig. S2) and the multivariate analyses showed no association between the 
absolute or relative expression and survival.
Associations between p53 isoform levels and clinicopathological parameters. No significant dif-
ferences in the p53 isoform expression were observed between the completely resected patients and the patients 
Figure 3. mRNA expression levels in individual tumour samples stratified for TP53 mutation status for (A). 
Total p53 mRNA, (B) p53β mRNA relative to total p53, (C) Δ133p53 mRNA relative to total p53, (D) p53γ 
mRNA relative to total p53. *Denotes significance level p ≤ 0.05 blue colour indicates unclassified TP53 
mutation, green colour denominates the LOF/hot spot TP53 mutation category.
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for whom complete resection could not be achieved. In addition, a comparison of the moderate and low differen-
tiated cases showed no differences in the p53 isoform levels. The expression of the p53γ isoform was associated 
with age when grouped by median (p = 0.044); however, the expression of the other isoforms showed no associ-
ation with patient age. The levels of the p53β isoform relative to the total p53 were significantly higher expressed 
in the FIGO stage III vs. IV (p = 0.05) specimens.
Clinical relevance of TP53 mutation status. The combined data for the TP53 mutation status and the 
p53 isoform expression were available for 31 patients. The main reason for this limited number of cases was lack 
of access to germline DNA (needed to distinguish somatic and germline variants detected in tumour). The known 
TP53 hotspot mutations, such as R248W, R175H and R273C, were among the mutations identified (see Table 4). 
The cases were categorised as follows: i) a group showing the LOF mutations or the above-mentioned hotspots 
(n = 9), ii) a TP53 wild-type group (n = 5) and iii) a group consisting of unclassified TP53 mutations (n = 17). 
The LOF and hotspot mutations were more commonly seen in the FIGO stage IV tumours (p = 0.003) and a low 
differentiation grade (p = 0.024).
The possible correlation of the TP53 mutation status with PFS as a surrogate for response to chemotherapy 
was tested. The patients carrying tumours with the three groups of mutations showed a significantly different 
response to chemotherapy (p = 0.029), with the unclassified mutations revealing the longest PFS when compared 
to the wild-type and the LOF/hotspot patients. Similar results were found with the univariate survival analysis 
Figure 4. Kaplan-Meier survival plots for differential survival in patients expressing. (A) Higher vs. lower than 
median levels of Δ133p53 relative to total p53. (B) Illustration of PFS in patients, divided by median expression 
of Δ133p53 mRNA. (C) Kaplan-Meier survival plot for patients carrying cancers classified as TP53 wild-type, 
LOF and hotspot mutations vs. other TP53 mutations.
Progression free survival Overall survival
HR (95% CI) P-value HR (95% CI) P-value
Age at diagnosis; in years 0.993 (0.956–1.031) 0.710 0.975 (0.931–1.021) 0.274
Tumor stage IIIC vs. IV 2.694 (1.259–5.765) 0.011 2.357 (1.092–5.088) 0.029
Residual disease; in cm 0 vs. >0 1.928 (0.911–4.077) 0.086 5.254 (1.481–18.642) 0.010
Δ133p53 High vs. Low 0.569 (0.315–1.027) 0.061
High vs. Low 0.422 (0.207–0.861) 0.018
Table 3. Prognostic and predictive impact of the p53 splice variant Δ133p53 for 69 women with HGSOC in 
multivariate Cox regression analysis. Δ133p53ratio denominates mRNA expression of Δ133p53 as a fraction of 
the total p53 levels.
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(logrank p = 0.002; Fig. 4C). When introducing a combined biomarker panel including the TP53 mutation classes 
and levels of p53 isoforms into a Kaplan-Meier univariate model, we did not observe an enhanced discrimination 
between the patient groups (data not shown).
Discussion
The ability to predict response to first-line chemotherapy in HGSOC is currently limited. Better biomarkers are 
needed to optimise the therapeutic regimen for the patients. There are a limited number of studies assessing the 
prognostic relevance of the p53 network, including the aberrant expression of p53 isoforms reported in various 
human malignancies13–17,23–26,29,30. By quantification of the mRNA levels of selected p53 isoforms in HGSOC 
tumour tissues, from patients carefully selected based on chemotherapy responses, we showed that the over-
expression of the total Δ133p53 isoforms was associated with prolonged OS and PFS in multivariate survival 
analyses. However, the p53 isoform levels were not found to be significantly differentially distributed when the 
chemoresistant and chemosensitive cohorts were compared. These results are in line with a previous study that 
identified the Δ133p53 isoforms (Δ133p53α,β,γ) as favourable prognostic factors in TP53 mutated, advanced 
serous ovarian cancers24. In contrast, Δ133p53β has been shown to promote invasion and cancer cell stemness 
in breast cancer cell lines and has been associated with impaired survival in patients with breast carcinomas16,17. 
The exact roles of Δ133p53 isoforms and the means by which they become tissue-specific therefore remain to be 
elucidated. Furthermore, the higher relative expression of p53β to total p53 was associated with FIGO stage IIIC; 
thus, it could be hypothesised that p53β plays a role in the metastatic potential. The p53β isoform is missing the 
transactivation and tetramerization domains that seem necessary for enabling the transcriptional competence of 
p5331, and the higher expression has been associated with tumour traits and favourable survival in other cancer 
types15,29.
The present data also revealed that the mRNA level of Δ133p53 was much higher than the levels of p53β and 
p53γ in most patients. This is in line with previous findings for uterine serous carcinomas26. While the p53β and 
p53γ isoform may still be important, one may speculate that the low levels of these mRNAs compared to the total 
levels of p53 mRNA may limit their prognostic influence. We found expression levels of p53 isoforms to be highly 
correlated with each other. One possible explanation for this relationship is the presence of simultaneous altera-
tions on both the amino- and carboxy-terminus of the protein. However, the isoform expression was not directly 
proportional to the total levels of p53 mRNA. It is therefore likely that isoforms are not merely a by-product of 






7577545 T > C M246Va 1 (4.8%) 0
7577579 G > C R248Wa* 1 (4.8%) 1 (7.1%)
7578406 C > T R175Ha* 0 1 (7.1%)
7574002CG > C FrameshiftR342* 1 (4.8%) 0
7578271 T > C H193Ra 1 (4.8%) 1 (7.1%)
7578190 T > C Y220Ca 0 1 (7.1%)
7577141 G > T G266Va 1 (4.8%) 0
7577536 T > A R249Wa 1 (4.8%) 0
7577121 G > A R273Ca* 0 1 (7.1%)
7577106 G > A P278Sa 1 (4.8%) 0
7577570 C > T M237Ia 1 (4.8%) 0
7577548 C > T G245Sa 1 (4.8%) 1 (7.1%)
7577577 T > C N235Sa 0 1 (7.1%)
7577509 C > A E258Xnonsensea* 0 1 (7.1%)
7578535 T > C K132Ra 1 (4.8%) 0
7572990CT > C FrameshiftK373* 0 1 (7.1%)
7574017 C > A R337La 1 (4.8%) 0
7578527 A > C C135Ga 1 (4.8%) 0
7578210 T > C R213R 1 (4.8%) 0
7579472 G > C P72Ra 2 (9.5%) 3 (21.4%)
7578271 T > A H193La 1 (4.8%) 0
7577556 C > G C242Sa 1 (4.8%) 0
7577121GCAC > G DeletionR273* 0 1 (7.1%)
7577122 C > G V272Va 0 1 (7.1%)
7578529 A > C F134Ca 1 (4.8%) 0
7578442 T > G Y163Sa 1 (4.8%) 0
7578442 T > A K120Xnonsense* 1 (4.8%) 0
Table 4. Overview over mutations detected in our cohort. aMutation has been reported earlier in the IARC 
archive39; *defined as hotspot or LOF mutation. Abbrevations: AA amino acid.
8Scientific RepoRts |          (2019) 9:5244  | https://doi.org/10.1038/s41598-019-41706-z
www.nature.com/scientificreportswww.nature.com/scientificreports/
isoforms by the splice machinery may reduce the wild-type transcript effect. Additionally, some of the cases ana-
lysed maybe possess a more general, inherent splice chaos.
The TP53 mutation status had predictive significance when the TP53 mutations were categorised into (i) a 
group with LOF mutations and common hotspots (R273, R248, R175) that was compared with the survival of 
patients bearing cancers (ii) with the TP53 wild-type tumours or (iii) other, unclassified TP53 defects. There are 
conflicting reports on the predictive value of different TP53 mutation types in HGSOC6,7,32. Similar to the findings 
in this study, other studies33 have also found the PFS in patients with TP53 wild-type tumours inferior to that of 
patients with non-canonical TP53 mutations. Because TP53 mutations are an almost universal observation in 
HGSOC4, the observed wild-type status could be questioned. It is possible that TP53 is inactivated by alternative 
mechanisms in the patients with no detected TP53 mutation.
A correlation was found between TP53 LOF and hotspot mutations and the FIGO stage IV tumours. This is in 
line with previous studies revealing differential effects of the various TP53 mutations. The TP53 mutations seem 
to have a differential oncogenic capacity, depending on the mutation site and resulting downstream effect5. The 
univariate analyses of the combined biomarker panels for the TP53 mutation classes and the expression of p53 
isoforms did not enhance the significance of the prognostic information. This might have been the result of the 
small number of patients analysed in each group (n = 5–8; data not shown).
The clinical assessment of the TP53 mutation status are regularly performed by immuno-histochemical stain-
ing34. This standard diagnostic approach is based on the accumulation of p53 protein in a majority of TP53 
mutated cases. This accumulation of p53 protein is seen as the result of an increased protein stability of mutant 
p53. Here, we found that the TP53 mutated specimens also had higher levels of total p53 mRNA, and this might 
have contributed to the resulting protein accumulation.
Notably, we found five patients to be TP53 wild-type. While, there is an ongoing debate whether TP53 muta-
tions are ubiquitous in HGSOC, it is noteworthy that large sequencing efforts, such as TCGA, have also found a 
fraction of HGSOC to be TP53 wild-type33. As such we believe our findings regarding mutational status, represent 
the true biology of our cases.
The small number of cases resulting from the rigorous exclusion of possible confounders must be regarded as 
limitation of this study. In addition, the expression of the total Δ40p53 isoform was not detected in the current 
experiments although this isoform has been detected in comparable series24. Although the current experimental 
setup enabled the quantitative detection of mRNAs containing the specific breakpoints for the different p53 iso-
forms, we were unable to reveal the combined breakpoints leading to alterations on both the carboxy-terminus 
and the amino-terminus (total ∆133p53 includes the pool of ∆133p53α, ∆133p53β and ∆133p53γ isoforms). 
Currently, such mRNAs can be detected only qualitatively and, at best, semi-quantitatively. It is possible that iso-
form subtypes may possess an even better prognostic impact in HGSOC and other cancer types.
The ability to predict a good response to first-line chemotherapy in HGSOC is a crucial milestone in the 
implementation of personalised medicine. The term ‘BRCAness’ was introduced to describe ovarian or breast 
tumours that share molecular features and drug sensitivity with BRCA-mutated tumours35. ‘BRCAness’ is associ-
ated with the response to PARP inhibitors, but no other molecular biomarkers play a role in the treatment strat-
ification for HGSOC. The findings of this study point to the Δ133p53 isoform as a potential biomarker, pending 
further validation.
Methods
Patient characteristics. The original cohort of 493 individuals represents a consecutive collection of all 
of the patients diagnosed with and treated for EOC at Haukeland University Hospital, Bergen, Norway, dur-
ing the period August 2001–June 2013. From this cohort, 40 patients with a good response to standard combi-
nation chemotherapy (‘responders’, defined as time to recurrence ≥17 months; n = 40) and 29 patients with a 
poor response to treatment (‘non-responders’, defined as progressive disease ≤6 months; n = 29) were selected 
to participate in the study. Advanced HGSOC was defined as FIGO stage IIIC or IV, high-grade (World Health 
Organization [WHO] Grade 2/3) serous histology and ovarian, primary peritoneal or fallopian origin. The patient 
demographic data and tumour traits, such as FIGO stage, as well as phenotypic characteristics, such as date of 
diagnosis and surgical treatment, level of complete cytoreduction and follow-up (at a mean of 41 months, range 
2–144 months) were available for analysis (see Table 1).
All of the patients included in the study were treated with primary cytoreductive surgery and clinically 
staged according to the FIGO 2014 criteria36. Surgical debulking was followed by platinum-based chemotherapy. 
Patients who were offered different treatment protocols, such as neoadjuvant chemotherapy and anti-angiogenic 
treatment, and patients who had concomitant cancers were excluded to avoid confounders. PFS was defined as 
the time interval, in months, between the date of the termination of adjuvant platinum-containing chemotherapy 
to the date of recurrence or last follow-up. OS was classified as an outcome measure and defined as the time inter-
val, in months, from the day of the primary surgery to the last follow-up date or death from disease. Two patients 
were excluded from this part of the analysis because of missing follow-up data.
The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethical 
committee (Regional Committees for Medical and Health Research Ethics Vest [REK], University of Bergen, 
Norway, id: 2018/72). The biological material and phenotypic data that formed the basis of this project are part 
of the Bergen Gynecologic Cancer Biobank, Women’s Clinic, Haukeland University Hospital, Bergen, Norway 
(REK id: 2014/1907 and 2015/548). In accordance with the local ethics committee’s guidelines, written informed 
consent was prospectively obtained from all of the women before the collection of fresh frozen tumour tissue, 
blood samples and clinicopathologic parameters was initiated.
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Tumour tissue. After collection at the time of primary diagnosis, the tissue specimens were immediately 
frozen in liquid nitrogen, and the clinical data were annotated. If there were multiple eligible primary biopsies, the 
ovarian mass was the preferred tumour site for analysis. The tumour content of the fresh frozen specimens was 
assessed in ethanol-fixed and hematoxylin- and eosin- stained sections. While the minimum cut-off for inclusion 
was set at 50%, the tumour purity was more than 80% in a majority of the included tissue samples (n = 39). The 
histopathological analysis was performed at the Haukeland University Hospital Department of Pathology. The 
specimens were fixed in buffered formaldehyde, embedded in paraffin and further processed in the laboratory 
before standard histological sections were made. Pathologists trained in gynaecologic oncology performed the 
diagnostic assessments.
Nucleic acid isolation and cDNA synthesis. DNA was isolated from the fresh frozen samples by tissue 
digestion at 65 °C in a lysis buffer containing NaCl, EDTA 0.5 M pH8.5, TrisM pH8, sodium dodecyl sulphate 
(SDS) 5%, proteinase K 20 mg/ml and H2O. Following overnight incubation, standard ethanol precipitation with 
sodium perchlorate and isopropanol was performed. DNA quantity was determined using a Qubit fluorom-
eter (Thermo Fisher Scientific, Waltham, MA, USA). RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. RNA quantification was performed using 
a NanoDrop M-1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). A total of 500 ng RNA was added to 20 μL reaction 
mix, and single-strand cDNA was synthesised using the Transcriptor Reverse Transcriptase system (Roche, Basel, 
Switzerland) according to the manufacturer’s protocol.
Quantitative real-time PCR. Quantitative real-time PCRs (qPCR) were performed using specific primers 
and hydrolysis probes (see Table-S1) targeting total TP53 or the different isoforms of TP53, as was previously 
described26. Importantly, this experimental setup enabled the quantitative detection of the mRNA production of 
p53 isoforms; however, it did not allow for discrimination between the full-length molecules and their respective 
isoforms exhibiting alterations on both the carboxy-terminus and the amino-terminus. This important limitation 
is caused by the limited amplicon length used for the real-time qPCR. The mRNAs of the detected and quantified 
TP53 were the total p53, total Δ133p53, p53β and p53γ isoforms.
TP53 sequencing and mutation calling. The targeted massive parallel sequencing of the tumour DNA 
generated data on the TP53 mutation status. The fragmentation of 1,000 ng dsDNA was achieved using the 
Covaris® M220 Focused-ultrasonicator™ (Covaris, Woburn, MA, USA). The library preparation was performed 
using the Agilent SureSelectXT reagent kit (Agilent Technologies, Santa Clara, CA, USA), and the individual sam-
ples were run on a MiSeq instrument (Illumina, San Diego, CA, USA). This design included +/−10 nucleotides 
at exon-intron borders, to cover potential splice site mutations. The TP53 data was extracted from a sequencing 
effort applying baits targeting 360 genes as previously described in detail37. Preliminary mutation calling was 
performed using the MiSeq Reporter (MSR) software, and the raw mutation calling output was revised by the 
application of post-processing filters. All of the suspected TP53 mutations were validated by the manual inspec-
tion of the sequencing reads using the Integrative Genomics Viewer38.
Statistical analyses. The Shapiro-Wilk test was performed to assess the normality assumption. On the 
basis of the non-normal distributed expression levels of total p53, total Δ40p53, total Δ133p53, p53β and p53γ 
isoforms, we calculated the Spearman’s rank-order correlation for those variables. The Mann-Whitney U- and 
Kruskal-Wallis tests were applied to investigate the associations among the continuous variables (age and iso-
form expression levels) and the categorical variables (age grouped by median, disease stage, histological grade, 
presence of complete cytoreduction and chemoresistance as well as TP53 mutation status). Fisher’s exact test 
and Pearson’s chi-squared test were used for comparisons of the categorical variables (patient age grouped by 
median, presence of complete cytoreduction, chemosensitivity and mutation status). The univariate survival anal-
ysis was performed by the Kaplan-Meier method, and subsets of patients (divided by median absolute or relative 
to total p53 expression of isoforms) were compared using the log-rank test. Multivariate survival analyses were 
performed using the Cox proportional-hazards regression model in a one-step fashion. Important clinical pre-
dictors of survival, such as age, FIGO stage and resection status, were added as categorical covariates. In the Cox 
proportional-hazards model, the absolute expression of the p53 isoforms and the isoform expression relative to 
the total p53 were tested as predictors. All of the p-values were reported as two-sided, and p-values < 0.05 were 
considered significant. The statistical analyses were performed using the SPSS 22.0 software package (SPSS Inc., 
Chicago, IL, United States of America).
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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